Search Results
You are looking at 1 - 7 of 7 items for
- Author: M Bauer x
- Refine by access: All content x
Search for other papers by M Bauer in
Google Scholar
PubMed
Search for other papers by N Parvizi in
Google Scholar
PubMed
Abstract
The ontogeny of GH and IGF-I secretion was investigated in the fetal pig. Pulse studies were performed to describe the pattern of GH release. Twenty-four-hour profiles were recorded to examine possible diurnal variations in these hormones.
(I) Pulse studies. Blood samples were obtained at 15-min intervals for 2-h periods from 24 male and 20 female fetuses at various gestational ages (fetal day 89–113; term 113 ± 1 s.d.). Fetuses revealed a pulsatile GH release. The GH pulse frequency did not vary with gestational age in either sex (0·95 ± 0·19 pulses/h). In males the GH pulse amplitude decreased with increasing fetal age (r= −0·41; P<0·02). In female fetuses no significant correlation could be calculated. Mean GH concentrations fell significantly in male fetuses 3 to 4 days before delivery (P<0·05) and the same tendency was observed in females (P<0·06). Between fetal days 94 and 98 GH pulse amplitude and GH and IGF-I concentrations were higher in males than in females (P<0·01, P<0·001 and P<0·02 respectively). Fetal IGF-I secretion showed no ontogenetic changes in both sexes. However, maternal IGF-I concentrations increased with progressing gestation (r=0·46; P<0·001).
(II) 24-h profiles. Eight male and four female late-gestational fetuses (fetal days 104–108) were studied. Blood samples were taken at 30-min intervals over 24 h. Dams and fetuses showed an episodic GH secretion over the 24-h period but no diurnal rhythm was observed. Whereas maternal IGF-I secretion was constant, fetal IGF-I release was characterized by marked fluctuations over the 24 h. In half of the fetuses (n=6) the fluctuations appeared at regular intervals. Again no diurnal rhythm existed.
These data demonstrated that: (1) porcine fetal GH secretion is pulsatile and decreases shortly before birth; (2) a sex difference in GH and IGF-I concentrations exists between fetal days 94 and 98, suggesting that IGF-I is at least partially under the control of GH before birth; (3) fetal GH and IGF-I secretion is episodic over 24 h, but does not vary diurnally; and (4) fetal and maternal GH and IGF-I secretion are regulated independently.
Journal of Endocrinology (1996) 149, 125–133
Search for other papers by M. Tepel in
Google Scholar
PubMed
Search for other papers by S. Bauer in
Google Scholar
PubMed
Search for other papers by S. Husseini in
Google Scholar
PubMed
Search for other papers by A. Raffelsiefer in
Google Scholar
PubMed
Search for other papers by W. Zidek in
Google Scholar
PubMed
ABSTRACT
Cytosolic free sodium concentrations ([Na+]i) in intact platelets from 32 type 2 (non-insulin-dependent) diabetic patients and from 27 age- and sex-matched non-diabetic control subjects were measured with the novel sodium-sensitive fluorescent dye sodium-binding-benzofuran-isophthalate. [Na+]i was significantly higher in platelets from type 2 diabetic patients compared with control subjects (40·6 ± 2·4 vs 32·0 ± 2·0 mmol/l, means ± s.e.m., P<0·03). Both systolic and diastolic blood pressure were significantly elevated in diabetic patients compared with control subjects. Analysis of diabetic patients showed a significant association between [Na+]i and diastolic blood pressure (P =0·026). Stimulation of Na/H exchange by thrombin increased [Na+]i in both groups. After inhibition of Na/K/ATPase by ouabain (1 mmol/l), [Na+]i was significantly increased both in diabetic patients and non-diabetic subjects in a similar way (by 40·2 ± 7·3 and 31·7 ± 5·3 mmol/l respectively). It is concluded that increased [Na+]i in cells from type 2 diabetic patients may be related to hypertension.
Journal of Endocrinology (1993) 138, 565–572
Search for other papers by E Ogawa in
Google Scholar
PubMed
Search for other papers by B H Breier in
Google Scholar
PubMed
Search for other papers by M K Bauer in
Google Scholar
PubMed
Search for other papers by P D Gluckman in
Google Scholar
PubMed
Abstract
The metabolic effects of ovine placental lactogen (oPL) alone and in combination with bovine GH (bGH) were investigated in comparison with the identical dose of bGH alone in the well-fed postnatal lamb. The animals were treated by twice daily intramuscular injection for 5 days with oPL (n=7), bGH (n=7) or bGH+oPL (n=7) at a dose of 0·3 mg/kg per day or saline (n=9). bGH and bGH+oPL treatments, but not oPL treatment, resulted in significantly (P<0·01) higher plasma IGF-I levels than saline treatment. The rate of net protein catabolism (NPC) was significantly (P<0·05) reduced to the same extent by bGH and bGH+oPL treatment compared with saline treatment. In contrast, oPL did not affect the rate of NPC. Blood glucose and insulin:glucose ratio were significantly (P<0·05) elevated in the bGH+oPL group, whereas they were not significantly altered by either bGH or oPL treatment. These results suggest that oPL alone is not somatogenic or anticatabolic in the postnatal lamb despite the earlier evidence that oPL can bind to the oGH receptor (oGHR). However, oPL appeared to augment some of the effects of bGH when administered together, particularly with respect to carbohydrate metabolism. Potentiation of the diabetogenic effect of bGH by oPL may lead to insulin resistance during pregnancy. The lack of any obvious actions by oPL treatment alone may support the hypothesis that oGHR homo-dimerization is required for the full activation of GHR-mediated effects, since oPL binding does not initiate homo-dimerization of the oGHR.
Journal of Endocrinology (1995) 145, 87–95
Search for other papers by Richard Truse in
Google Scholar
PubMed
Search for other papers by Fabian Voß in
Google Scholar
PubMed
Search for other papers by Anna Herminghaus in
Google Scholar
PubMed
Search for other papers by Jan Schulz in
Google Scholar
PubMed
Search for other papers by Andreas P M Weber in
Google Scholar
PubMed
Search for other papers by Tabea Mettler-Altmann in
Google Scholar
PubMed
Search for other papers by Inge Bauer in
Google Scholar
PubMed
Search for other papers by Olaf Picker in
Google Scholar
PubMed
Search for other papers by Christian Vollmer in
Google Scholar
PubMed
During circulatory shock, gastrointestinal microcirculation is impaired, especially via activation of the renin-angiotensin-aldosterone system. Therefore, inhibition of the renin-angiotensin-aldosterone system might be beneficial in maintaining splanchnic microcirculation. The aim of this study was to analyze whether locally applied losartan influences gastric mucosal perfusion (µflow, µvelo) and oxygenation (µHbO2) without systemic hemodynamic changes. In repetitive experiments six anesthetized dogs received 30 mg losartan topically on the oral and gastric mucosa during normovolemia and hemorrhage (−20% blood volume). Microcirculatory variables were measured with reflectance spectrometry, laser Doppler flowmetry and incident dark field imaging. Transpulmonary thermodilution and pulse contour analysis were used to measure systemic hemodynamic variables. Gastric barrier function was assessed via differential absorption of inert sugars. During normovolemia, losartan increased gastric µflow from 99 ± 6 aU to 147 ± 17 aU and µvelo from 17 ± 1 aU to 19 ± 1 aU. During hemorrhage, losartan did not improve µflow. µvelo decreased from 17 ± 1 aU to 14 ± 1 aU in the control group. Application of losartan did not significantly alter µvelo (16 ± 1 aU) compared to the control group and to baseline levels (17 ± 1 aU). No effects of topical losartan on macrohemodynamic variables or microcirculatory oxygenation were detected. Gastric microcirculatory perfusion is at least partly regulated by local angiotensin receptors. Topical application of losartan improves local perfusion via vasodilation without significant effects on systemic hemodynamics. During mild hemorrhage losartan had minor effects on regional perfusion, probably because of a pronounced upstream vasoconstriction.
Search for other papers by S Shaikh in
Google Scholar
PubMed
Search for other papers by F H Bloomfield in
Google Scholar
PubMed
Search for other papers by M K Bauer in
Google Scholar
PubMed
Search for other papers by H H Phua in
Google Scholar
PubMed
Search for other papers by R S Gilmour in
Google Scholar
PubMed
Search for other papers by J E Harding in
Google Scholar
PubMed
We have previously reported that chronic intra-amniotic supplementation of the late gestation growth-restricted (IUGR) ovine fetus with IGF-I (20 μg/day) increased gut growth but reduced liver weight and circulating IGF-I concentrations. Here we report mRNA and protein levels of IGF-I, the type 1 IGF receptor (IGF-1R) and IGF-binding proteins (IGFBP)-1, -2 and -3 in fetal gut, liver, muscle and placenta from fetuses in that earlier study in an attempt to explain these contrasting results. mRNA and protein were extracted from tissues obtained at post mortem at 131 days of gestation (term, 145 days) from three groups of fetuses (control, IUGR+saline and IUGR+IGF-I, n=9 per group). Control fetuses were unembolised and untreated. In the IUGR groups, growth restriction was induced from 113 to 120 days by placental embolisation; from 120 to 130 days fetuses were treated with daily intra-amniotic injections of either saline or 20 μg IGF-I. mRNA was measured by RT-PCR or real-time RT-PCR, and protein by Western blot. In liver, muscle and placenta, IGF-I mRNA and protein levels were reduced by between 8 and 30% in IGF-I-treated fetuses compared with saline-treated fetuses and controls with no change in IGF-1R mRNA or protein levels. In contrast, in the gut, IGF-I mRNA and protein levels were not significantly altered with IGF-I treatment, but IGF-1R levels were increased, especially in the jejunum. Immunolocalisation demonstrated that IGF-1R expression was confined to the luminal aspect of the gut. mRNA levels of all three IGFBPs were reduced in the gut of IGF-I-treated fetuses, but hepatic expression was significantly increased. These data demonstrated tissue-specific regulation of IGF-I, IGF-1R and IGFBPs-1, -2 and -3 in response to intra-amniotic IGF-I supplementation, though the underlying mechanisms remain obscure.
Search for other papers by W Klootwijk in
Google Scholar
PubMed
Search for other papers by R D H de Boer in
Google Scholar
PubMed
Search for other papers by E Sleddens-Linkels in
Google Scholar
PubMed
Search for other papers by S M Cockle in
Google Scholar
PubMed
Search for other papers by W W de Herder in
Google Scholar
PubMed
Search for other papers by K Bauer in
Google Scholar
PubMed
Search for other papers by T J Visser in
Google Scholar
PubMed
Search for other papers by W J de Greef in
Google Scholar
PubMed
Abstract
TRH-like immunoreactivity (TRH-LI) was estimated in methanolic extracts of rat tissues and blood by RIA using antiserum 4319, which binds most peptides with the structure pGlu-X-ProNH2, or antiserum 8880, which is specific for TRH (pGlu-His-ProNH2). TRH-LI (determined with antiserum 4319) and TRH (determined with antiserum 8880) contents were 8 and 8 ng/g in brain, 216 and 222 ng/g in hypothalamus, 6·5 and 6 ng/g in pancreas, 163 and 116 ng/g in male pituitary, 105 and 77 ng/g in female pituitary, 1 and 0·1 ng/g in salivary gland, 61 and 42 ng/g in thyroid, 12 and 3 ng/g in adrenal, 3 and 0·3 ng/g in prostate, and 11 and 0·8 ng/g in ovary respectively. Blood TRH-LI (antiserum 4319) and TRH (antiserum 8880) levels were 31 and 18 pg/ml in male rats, and 23 and 10 pg/ml in female rats respectively. Unextracted serum obtained from blood kept for at least 1 h at room temperature no longer contained authentic TRH but still contained TRH-LI (males 20·3 ± 3·1, females 15·9 ± 3·0 pg/ml; means ± s.e.m.). Isocratic reverse-phase HPLC showed that TRH-LI in serum is largely pGlu-Glu-ProNH2 (<EEP-NH2), a peptide previously found in prostate and anterior pituitary.
In urine, TRH-LI (antiserum 4319) and TRH (antiserum 8880) levels were 3·21 ± 0·35 and 0·32 ± 0·04 ng/ml in male rats and 3·75 ± 0·22 and 0·37 ± 0·04 ng/ml in female rats respectively (means ± s.e.m.). Anion-exchange chromatography on QAE-Sephadex showed that urine of normally fed rats contains both basic/neutral TRH-LI (b/nTRH-LI) and acidic TRH-LI (aTRH-LI) in a ratio of ≈ 40:60, and further analysis by HPLC indicated that aTRH-LI represents <EEP-NH2. Analysis of food extracts and urine from fasted rats demonstrated that b/nTRH-LI is derived from food particles spilled by the rats during urine collection, while aTRH-LI is endogenously produced. While urinary aTRH-LI levels were higher in female than in male rats (2·99 ± 0·41 vs 2·04 ± 0·20 ng/ml), the daily urinary excretion was similar in both sexes (females 15·6 ± 1·4, males 19·5 ± 2·0 ng/day). Intravenously injected <EEP-NH2 disappeared from serum with a half-life of ≈ 1 h, and was recovered unchanged and quantitatively in urine. In contrast, when <EEP-NH2 was administered with food, only ≈ 0·5% was recovered in urine. The urinary clearance rate of serum TRH-LI amounted to 0·52 ± 0·10 ml/min in males and 0·34 ± 0·05 ml/min in females.
In view of the presence of <EEP-NH2 in the anterior pituitary gland, and the regulation of its content in parallel with gonadotrophins, we examined the possibility that serum <EEP-NH2 is of pituitary origin and correlates with gonadotrophin secretion. However, treatments that alter pituitary <EEP-NH2 content and gonadotrophin release had no effect on serum TRH-LI or urinary aTRH-LI.
In conclusion, the TRH-like peptide <EEP-NH2 is present in rat serum and is excreted into the urine. Moreover, <EEP-NH2 in serum and urine is not derived from rat food and is probably not of pituitary origin.
Journal of Endocrinology (1997) 153, 411–421
Search for other papers by G A C van Haasteren in
Google Scholar
PubMed
Search for other papers by E Linkels in
Google Scholar
PubMed
Search for other papers by W Klootwijk in
Google Scholar
PubMed
Search for other papers by H van Toor in
Google Scholar
PubMed
Search for other papers by J M M Rondeel in
Google Scholar
PubMed
Search for other papers by A P N Themmen in
Google Scholar
PubMed
Search for other papers by F H de Jong in
Google Scholar
PubMed
Search for other papers by K Valentijn in
Google Scholar
PubMed
Search for other papers by H Vaudry in
Google Scholar
PubMed
Search for other papers by K Bauer in
Google Scholar
PubMed
Search for other papers by T J Visser in
Google Scholar
PubMed
Search for other papers by W J de Greef in
Google Scholar
PubMed
Abstract
The purpose of this study was to investigate the mechanisms involved in the reduced thyroid function in starved, young female rats. Food deprivation for 3 days reduced the hypothalamic content of prothyrotrophin-releasing hormone (proTRH) mRNA, the amount of proTRH-derived peptides (TRH and proTRH160–169) in the paraventricular nucleus, the release of proTRH-derived peptides into hypophysial portal blood and the pituitary levels of TSHβ mRNA. Plasma TSH was either not affected or slightly reduced by starvation, but food deprivation induced marked increases in plasma corticosterone and decreases in plasma thyroid hormones. Refeeding after starvation normalized these parameters. Since the molar ratio of TRH and proTRH160–169 in hypophysial portal blood was not affected by food deprivation, it seems unlikely that proTRH processing is altered by starvation. The median eminence content of pGlu-His-Pro-Gly (TRH-Gly, a presumed immediate precursor of TRH), proTRH160–169 or TRH were not affected by food deprivation. Since median eminence TRH-Gly levels were very low compared with other proTRH-derived peptides it is unlikely that α-amidation is a rate-limiting step in hypothalamic TRH synthesis.
Possible negative effects of the increased corticosterone levels during starvation on proTRH and TSH synthesis were studied in adrenalectomized rats which were treated with corticosterone in their drinking water (0·2 mg/ml). In this way, the starvation-induced increase in plasma corticosterone could be prevented. Although plasma levels of thyroid hormones remained reduced, food deprivation no longer had negative effects on hypothalamic proTRH mRNA, pituitary TSHβ mRNA and plasma TSH in starved adrenalectomized rats. Thus, high levels of corticosteroids seem to exert negative effects on the synthesis and release of proTRH and TSH. This conclusion is corroborated by the observation that TRH release into hypophysial portal blood became reduced after administration of the synthetic glucocorticosteroid dexamethasone.
On the basis of these results, it is suggested that the reduced thyroid function during starvation is due to a reduced synthesis and release of TRH and TSH. Furthermore, the reduced TRH and TSH synthesis during food deprivation are probably caused by the starvation-induced enhanced adrenal secretion of corticosterone.
Journal of Endocrinology (1995) 145, 143–153